ASH SPECIAL ISSUE REVIEW PAPER
Central Sympatholytic Drugs
Article first published online: 18 JUL 2011
© 2011 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 13, Issue 9, pages 658–661, September 2011
How to Cite
Vongpatanasin, W., Kario, K., Atlas, S. A. and Victor, R. G. (2011), Central Sympatholytic Drugs. The Journal of Clinical Hypertension, 13: 658–661. doi: 10.1111/j.1751-7176.2011.00509.x
- Issue published online: 6 SEP 2011
- Article first published online: 18 JUL 2011
J Clin Hypertens (Greenwich). 2011;13:658–661. ©2011 Wiley Periodicals, Inc.
- •Central sympatholytic drugs reduce blood pressure mainly by stimulating central α2-adrenergic receptors in the brainstem centers, thereby reducing sympathetic nerve activity and neuronal release of norepinephrine to the heart and peripheral circulation.
- •This class of drugs, however, is currently used mainly as fourth-line (or beyond) drug therapy for hypertension because of side effects of drowsiness, fatigue, and dry mouth.
- •Rebound hypertension is also another major concern in certain drugs with a short half-life, particularly in patients who are nonadherent to the regimen. Therefore, their use on a “PRN” basis for treatment of blood pressure surge in the absence of symptoms or acute target complications should also be avoided.